secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theriva Biologics, Inc. (TOVX)
CIK:        0000894158
Form:       8-K
Filed at:   2024-10-03T23:59:59+00:00
Accession:  0001104659-24-105634
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theriva Biologics DSMC recommends advancing SYN-004 trial to Cohort 3 after positive Cohort 2 safety data
--------------------------------------------------------------------------------

- DSMC reviewed safety and PK data from Cohort 2 (19 patients) and recommended study proceed to Cohort 3 using cefepime.
- No SAEs or AEs determined related to study drug; 15 SAEs reported among 10 patients typical for allo-HCT.
- No patient blood samples positive for SYN-004 at any timepoint; piperacillin PK as expected.
- Company pursuing additional funding to enable Cohort 3 conduct; Phase 1b/2a trial remains blinded.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/894158/000110465924105634/0001104659-24-105634-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/894158/000110465924105634/tm2425487d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-105634

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer